Skip to main content
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. — Investor Relations & Filings

Ticker · MAZE ISIN · US5787841007 US Manufacturing
Open in API
Filings indexed 139 across all filing types
Latest filing 2025-01-27 Capital/Financing Update
Country US United States of America
Listing US MAZE

About Maze Therapeutics, Inc.

https://www.mazetx.com/

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that harnesses insights from human genetics to develop novel, small molecule precision medicines. The company utilizes its proprietary Compass platform, which leverages variant functionalization, to identify and validate new therapeutic targets. Maze's strategy focuses on designing medicines that imitate the effects of rare, naturally occurring, protective genetic variants to address common diseases with significant unmet medical needs. Its pipeline is focused on advancing treatments for renal and cardio-metabolic indications, with a lead program targeting APOL1-mediated kidney disease (AMKD).

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC for Maze Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the offering, company overview, risk factors, management discussion, and financial data index. This type of filing is a registration statement for securities offering under the Securities Act of 1933, not a financial report like an annual or quarterly report, nor an earnings release or other categories listed. The S-1/A is a capital markets filing related to the company's financing and capital raising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement but the actual registration statement amendment filing.
2025-01-27 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Maze Therapeutics, Inc. to the U.S. Securities and Exchange Commission regarding comments on their Registration Statement on Form S-1 filed on January 7, 2025. It includes detailed financial disclosures, notes to condensed financial statements, and proposed revisions to the Registration Statement. The content focuses on the company's IPO registration process, stock option repricing, valuation methodologies, and employment agreements related to the offering. The presence of Form S-1 and the nature of the content indicate this is related to a registration statement for an initial public offering or similar capital raising event. This is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a regulatory filing responding to SEC comments on a registration statement, which fits best under Regulatory Filings (RNS).
2025-01-21 English
Regulatory Filings 2025
Regulatory Filings
2025-01-16 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a detailed letter addressed to the SEC Division of Corporation Finance regarding Maze Therapeutics, Inc.'s Registration Statement on Form S-1 for an IPO. It discusses valuation methodologies for equity awards, preliminary IPO price range, and fair value determinations of common stock. The content is focused on regulatory review and valuation disclosures related to the IPO registration process. It is not a full financial report, earnings release, or management discussion, but rather a correspondence letter supplementing the Form S-1 registration statement. The presence of confidential treatment requests and detailed valuation explanations aligns with a regulatory filing related to the IPO registration process. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a correspondence letter to the SEC staff regarding the registration statement and valuation issues, not the registration statement itself or a financial report.
2025-01-10 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding Amendment No. 5 to a Draft Registration Statement on Form S-1 for Maze Therapeutics, Inc. It references the confidential submission of the Draft Registration Statement and the filing of the Registration Statement on Form S-1. The content is focused on addressing SEC comments and revising disclosures in the Registration Statement. The document is not the Registration Statement itself but a correspondence related to the registration process. It is a regulatory communication related to securities registration, not a financial report, earnings release, or other specific filing type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other categories.
2025-01-07 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated January 7, 2025, for Maze Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the offering, company overview, risk factors, management, executive compensation, and financial statements index. Form S-1 is a registration statement used by companies planning to go public to register their securities with the SEC. This type of filing is distinct from annual reports, earnings releases, or other filings. It is a capital markets filing related to the company's initial public offering and fundraising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or certification, so it is not RPA or RNS.
2025-01-07 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.